- Home
- CSTL vs DNUT Comparison
CSTL vs DNUT Comparison
Compare CSTL & DNUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- DNUT
- Stock Information
- Founded
- CSTL 2007
- DNUT 1937
- Country
- CSTL United States
- DNUT United States
- Employees
- CSTL N/A
- DNUT N/A
- Industry
- CSTL Medical Specialities
- DNUT Food Chains
- Sector
- CSTL Health Care
- DNUT Consumer Staples
- Exchange
- CSTL Nasdaq
- DNUT Nasdaq
- Market Cap
- CSTL 471.5M
- DNUT 505.6M
- IPO Year
- CSTL 2019
- DNUT 2021
- Fundamental
- Price
- CSTL $19.36
- DNUT $3.08
- Analyst Decision
- CSTL Strong Buy
- DNUT Buy
- Analyst Count
- CSTL 6
- DNUT 7
- Target Price
- CSTL $37.67
- DNUT $7.35
- AVG Volume (30 Days)
- CSTL 554.7K
- DNUT 16.2M
- Earning Date
- CSTL 08-04-2025
- DNUT 08-07-2025
- Dividend Yield
- CSTL N/A
- DNUT 4.54%
- EPS Growth
- CSTL N/A
- DNUT N/A
- EPS
- CSTL N/A
- DNUT N/A
- Revenue
- CSTL $346,269,000.00
- DNUT $1,538,841,000.00
- Revenue This Year
- CSTL N/A
- DNUT N/A
- Revenue Next Year
- CSTL $1.62
- DNUT $2.30
- P/E Ratio
- CSTL N/A
- DNUT N/A
- Revenue Growth
- CSTL 20.40
- DNUT N/A
- 52 Week Low
- CSTL $14.59
- DNUT $2.50
- 52 Week High
- CSTL $35.84
- DNUT $12.68
- Technical
- Relative Strength Index (RSI)
- CSTL 58.66
- DNUT 40.59
- Support Level
- CSTL $18.81
- DNUT $2.90
- Resistance Level
- CSTL $21.33
- DNUT $3.74
- Average True Range (ATR)
- CSTL 0.92
- DNUT 0.46
- MACD
- CSTL 0.45
- DNUT -0.10
- Stochastic Oscillator
- CSTL 70.74
- DNUT 6.36
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.